ConexiantBeta-Blockers Following MI: Still Needed?

Beta-blocker therapy showed no cardiovascular benefit in post-MI patients with preserved ejection fraction (≥50%) across a pooled analysis of nearly 20,000 patients. All-cause mortality, cardiovascular death, recurrent MI, heart failure, and revascularization rates were similar regardless of beta-blocker use over 3.5 to 5 years.

⚖️ CLINICAL CONSIDERATIONS

• Meta-analysis challenges routine long-term beta-blocker continuation in post-MI patients with preserved EF, contradicting traditional guideline-based practice patterns
• Findings suggest baseline ventricular function determines treatment effect, with preserved EF patients receiving no mortality or morbidity reduction from beta-blockers
• Contemporary MI care advances (early PCI, optimized antiplatelet therapy, statins, RAAS inhibitors) may diminish historical beta-blocker benefits in this population
• Current guidelines recommend early post-MI beta-blocker initiation, but optimal therapy duration and patient selection criteria remain undefined for preserved EF cohort

🎯 PRACTICE APPLICATIONS

• Reassess continuation of beta-blockers beyond acute phase in preserved EF post-MI patients
• Document shared decision-making conversations when discontinuing long-term beta-blocker therapy in appropriate candidates
• Prioritize proven therapies (dual antiplatelet, high-intensity statin, ACE inhibitor/ARB) over reflexive beta-blocker continuation
• Monitor emerging trial data defining optimal duration and patient selection for post-MI beta-blocker therapy

More on MI